TrialThe Lancet. Oncology2025

Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.

Elena Elimova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.